Alembic US branded push: Pivya launch and FY26 cues

The shift: from US generics to US branded prescriptions

Alembic Pharmaceuticals is widening its US strategy beyond generics by building a branded prescriptions business. The trigger is sustained pricing pressure in US generics, which management has cited as a reason to add a “different business” alongside its established portfolio. The company has launched its US branded business through Alembic Therapeutics, a step-down wholly owned subsidiary. The debut product is Pivya (pivmecillinam), positioned in women’s health.

Management described the move as a long-term value creation avenue, with the first year framed as investment-heavy and growth expected to follow from the second year onward. The company has also indicated it will set up its own marketing front end in the US, starting with high-prescribing therapeutic regions and then expanding the field footprint. The US is a meaningful part of the revenue mix, with one disclosure stating the US accounts for about a third of revenue, and another stating the US business accounts for 28% of revenue in FY24.

Utility Therapeutics acquisition: the entry ticket to branded US

Alembic’s entry into the US branded market is anchored by its acquisition of UK-based Utility Therapeutics. The acquisition was structured as a $12 million deal (around ₹100 crore) with milestone-linked, staggered payments. The company has said the acquisition is aimed at strengthening its US presence and expanding into branded prescription products.

Utility’s lead asset, Pivya, is central to this strategy. Alembic has characterised the acquisition as a strategic entry into specialty and branded prescription products. The underlying logic is that branded products can offer better economics than commodity generics, where pricing pressure is persistent.

Pivya: product positioning and regulatory backdrop

Pivya is positioned as a first-line oral antibiotic for uncomplicated urinary tract infections (uUTIs) in women. The company has highlighted that the segment has seen limited innovation and new product introductions for over a decade. In the US, management cited a market backdrop of about 30 million prescriptions written annually for uUTIs.

The product’s regulatory milestone is clear. Pivya, described as the first new antibiotic for uUTIs in women in nearly two decades, was approved by the USFDA in April 2024. Management has also pointed to the product’s established use in Europe for over 40 years, supporting a well-understood safety and efficacy profile. In commentary on its women’s health relevance, the company has highlighted its safety profile, including during pregnancy.

Q4FY26: segment performance reported for the quarter

In one quarterly disclosure, Alembic reported growth across key segments. Its India-branded business grew 4% year-on-year to ₹568 crore during the quarter. International business grew 11% year-on-year to ₹564 crore, led by the US formulations segment. Ex-US generics contributed ₹369 crore, and the company received four ANDA approvals during the quarter. The API business reported 2% year-on-year growth to ₹347 crore.

Management said Q4FY26 reflected disciplined execution, with revenue growth across key segments and healthy pre-R&D operating margins. It also flagged continued investments for long-term growth. The quarter was also used to mark the company’s entry into the US branded business with the commercial launch of Pivya.

Another performance snapshot: India ₹652 crore, ex-US ₹406 crore

A separate performance snapshot cited India Branded Business revenue rising 6% to ₹652 crore, driven by gynaecology, ophthalmology and animal health. The same snapshot said US generics grew 6% to ₹553 crore and ex-US generics surged 36% to ₹406 crore.

Because these figures are presented alongside the US branded-market entry narrative, they add context on therapy drivers and the pace of growth outside the US generics core. They also underline why Alembic is balancing multiple levers at once: domestic growth engines, non-US momentum, and a reset of its US model.

Product pipeline: launches and regulatory approvals

For the reported quarter, Alembic said it launched six products in the US market. Alongside those launches, the company received four ANDA approvals, strengthening the future product portfolio. In an earlier update on launch cadence, management said it was planning to launch 25 products in the US generics segment in FY25.

On the investment side, Alembic has previously targeted R&D spending of ₹550-₹600 crore in FY25, primarily for a US-focused pipeline that includes complex formulations such as injectables, ophthalmic, oncology, inhalation and dermatology products. In another disclosure on its longer build-up, the company said it has spent about ₹700-₹750 crore per annum on R&D and spent more than ₹1,800 crore to build three USFDA-compliant facilities.

GLP-1 interest: evaluating Semaglutide, near-term Tirzepatide focus

In comments to ETPharma, Managing Director Pranav Amin said the company is evaluating Semaglutide, but that Tirzepatide is the near-term focus where Alembic is aiming to catch the “first wave.” The statement highlights that Alembic is watching fast-moving therapy areas while it executes on its core generics and the new US branded strategy.

The company has also said it is cautiously exploring biosimilars, citing recent US FDA changes that lowered preclinical and clinical entry barriers. Management indicated it may look at partnerships or licensing, and that biosimilars is not an area Alembic has done yet.

What MOFSL flagged: growth, pressure points, and estimate cuts

Motilal Oswal Financial Services (MOFSL) noted that Alembic’s US business recorded a moderate 7% year-on-year growth in FY26 in constant currency terms, despite a healthy pace of product launches. It also said acute therapies remained largely flat for the fourth consecutive year, while the speciality segment continued to face pressure during FY26.

MOFSL added that animal health and non-US businesses sustained strong growth momentum, partially offsetting weakness in other segments. It said the company is focusing on scaling up its branded products business in the US market, but is awaiting clarity on prescription growth and expansion in doctor outreach given the recent launches.

The brokerage lowered its FY27 and FY28 earnings estimates by 12% and 6%, respectively, citing slower growth in branded generics in the domestic formulations segment, higher product development expenses, and weaker operating leverage. It expects EBITDA and PAT CAGR of 21% and 26% over FY26-FY28, supported by scale-up in the US business, increasing launches, growth in US branded products, and momentum in the non-US and API segments, while also noting the valuation already factors in much of the potential upside.

Key numbers table: reported quarterly metrics and milestones

Timeline table: Alembic’s US strategy milestones

Market impact: what changes for investors and the business mix

The immediate market relevance is Alembic’s attempt to improve its US mix by adding branded prescriptions to a generics business facing pricing pressure. Execution variables, based on the company and brokerage commentary, include prescription growth for Pivya, the pace of doctor outreach as the branded sales force ramps up, and the flow of US launches and ANDA approvals that support the generics base.

In parallel, quarterly numbers show that non-US and API segments continue to contribute meaningfully, with reported growth in India branded, international and API lines. Brokerage commentary adds that animal health and non-US strength is important because it helps offset pressure in acute and specialty areas and moderates the impact of US-market volatility.

Conclusion

Alembic’s acquisition of Utility Therapeutics and the commercial launch of Pivya mark a clear step into the US branded prescriptions market, alongside ongoing US generics launches and approvals. Quarterly disclosures show growth across India branded, international and API segments, while broker commentary highlights both US pricing pressure and the need for clarity on branded prescription traction. Next cues are likely to come from prescription ramp-up for Pivya, expansion of doctor outreach, and the company’s cadence of US product launches and approvals.